A former world champion middle-distance runner from Belarus has been temporarily suspended for doping after testing positive for a drug that has been in clinical trials to treat muscle wasting.
The Athletics Integrity Unit (AIU) said on August 27 that 31-year-old Marina Arzamasova has been notified of the allegation, one month before the world championships in Qatar.
The AIU was formed by the International Association of Athletics Federations (IAAF) in April 2017 to combat doping in the sport of athletics.
Arzamasova's case involves LGD-4033, better known as Ligandrol, the AIU said. Ligandrol is reportedly used in supplements by body builders to build muscle mass with fewer side effects than steroids.
Arzamasova won the 800 meters at the 2015 world championships in Beijing and was European champion in 2014. She placed seventh at the 2016 Rio de Janeiro Olympics.
The AIU operates fully independently from the IAAF.
Former Belarusian World Champion Runner Suspended For Doping
Editors' Picks
Top Trending
1
Putin Sends Signals To The West On Ukraine Ahead Of Trump's New Term
2Russia Moving Military Assets To Africa After Syria Setback
3Ukraine Hits Kazan Buildings In Latest Display Of Drone Power
4What Would The Russian Capture Of Pokrovsk Mean For The Ukraine War?
5Mystery Photos Shed Light On Romania's 1989 Revolution
6Orban Says Higher NATO Defense Targets Would Cripple The Hungarian Economy
7U.S., U.K. Say Medvedev's Comment Calling NATO Officials 'Legitimate Targets' Irresponsible
8Kyiv Hits Kursk After Massive Wave Of Deadly Russian Strikes On Ukraine
9Putin, In Annual Televised Show Of Control, Says Russia Nearing 'Primary Goal' In Ukraine War
10Russia's Runaway Food Prices
RFE/RL has been declared an "undesirable organization" by the Russian government.
If you are in Russia or the Russia-controlled parts of Ukraine and hold a Russian passport or are a stateless person residing permanently in Russia or the Russia-controlled parts of Ukraine, please note that you could face fines or imprisonment for sharing, liking, commenting on, or saving our content, or for contacting us.
To find out more, click here.
